The Technical Analyst
Longboard [LBPH]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Longboard Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.57% $19.75
America/New_York / 24 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 711.34 mill |
| EPS: | -2.39 |
| P/E: | -8.26 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 36.02 mill |
| Avg Daily Volume: | 0.593 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -8.26 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.41x |
| Company: PE -8.26 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.610 (-96.91%) $-19.14 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 18.25 - 21.23 ( +/- 7.54%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-08 | Kaye Randall | Buy | 107 560 | Stock Option (Right to Buy) |
| 2024-02-08 | Kaye Randall | Buy | 17 920 | Common Stock |
| 2024-02-08 | Roberts Brandi | Buy | 90 580 | Stock Option (Right to Buy) |
| 2024-02-08 | Roberts Brandi | Buy | 15 090 | Common Stock |
| 2024-02-08 | Lind Kevin Robert | Buy | 332 134 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| -62.75 |
| Last 48 transactions |
| Buy: 2 180 330 | Sell: 4 964 362 |
Forecast:
16:00 - $19.73
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $19.73
Forecast 2: 16:00 - $19.73
Forecast 3: 16:00 - $19.73
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $19.75 (-2.57% ) |
| Volume | 0.304 mill |
| Avg. Vol. | 0.593 mill |
| % of Avg. Vol | 51.31 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LBPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:36 | sell | $19.15 | N/A | Active |
|---|
LBPH
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical product candidates include LP659 and LP143, which focuses on developing therapies for multiple neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.
Latest Press Releases
2024-04-03 09:00:00 - Press Release
Longboard Pharmaceuticals To Present Late-breaking Data From The Pacific Study At The American Academy Of Neurology (aan) Annual Meeting On April 15
La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that dr. randall kaye, longboard's chief medical officer, will present late-breaking data from the pacific study evaluating bexicaserin, an oral, centrally acting 5-ht2c receptor superagonist, in participants with developmental and epileptic encephalopathies (dees) at the aan.
2024-04-02 16:00:00 - Press Release
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to three new employees. the compensation committee of the board of directors of longboard approved the grants of non-qualified stock options to purchase an aggregate of 99,500 shares of its common stock (the “common stock”) as inducements materi.
2024-03-12 16:01:00 - Press Release
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results And Provides Corporate Updates
La jolla, calif.--(business wire)--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported full year 2023 financial results. “i am extremely proud of what our team has accomplished starting with the immense effort that went into the pacific study in participants with dees. we are impressed with the data in this study showing evidence.
2024-03-01 16:01:00 - Press Release
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. the compensation committee of the board of directors of longboard approved the grants of non-qualified stock options to purchase an aggregate of 184,000 shares of its common stock (the “common stock”) as inducements materi.
2024-02-02 16:30:00 - Press Release
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to five new employees. the compensation committee of the board of directors of longboard approved the grants of non-qualified stock options to purchase an aggregate of 145,475 shares of its common stock (the “common stock”) as inducements materi.
Latest News
2024-01-05 10:34:20 - Zacks Investment Research
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2024-01-05 08:15:00 - MarketBeat
This biotech stock has surged over 300% this week
As the market continues to witness a resurgence in small-cap investments, led by a jump in investor optimism and speculation, there's been a seemingly steady flow of capital back into traditionally riskier sectors.
2024-01-02 13:06:30 - InvestorPlace
Why Is Longboard Pharmaceuticals (LBPH) Stock Up 175% Today?
Clinical-stage biopharmaceutical firm Longboard Pharmaceuticals (NASDAQ: LBPH ) got the new year off to the best start possible with a dramatic run. Earlier Tuesday morning, management disclosed positive topline data for its therapeutic bexicaserin, which addresses seizures in patients with developmental and epileptic encephalopathies (DEEs).
2024-01-02 11:41:50 - Proactive Investors
Longboard Pharmaceuticals stock soars on seizure drug results
Longboard Pharmaceuticals Inc shares surged 181% to $16.96 in late-morning trading on Tuesday after the clinical-stage biopharmaceutical company revealed positive topline data from its PACIFIC Study evaluating bexicaserin, which reduced seizures by 53.3% across a population of patients with developmental and epileptic encephalopathies (DEE). Longboard noted the phase 1b/2a study included 52 patients ages 12 to 65 years old with different seizure disorders, including Lennox-Gastaut syndrome and Dravet syndrome.
2023-05-01 09:55:20 - Zacks Investment Research
Longboard Pharmaceuticals, Inc. (LBPH) is on the Move, Here's Why the Trend Could be Sustainable
Longboard Pharmaceuticals, Inc. (LBPH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
2023-04-14 09:52:22 - Zacks Investment Research
Recent Price Trend in Longboard Pharmaceuticals, Inc. (LBPH) is Your Friend, Here's Why
Longboard Pharmaceuticals, Inc. (LBPH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2023-04-07 11:29:11 - Zacks Investment Research
Does Longboard Pharmaceuticals, Inc. (LBPH) Have the Potential to Rally 208.22% as Wall Street Analysts Expect?
The mean of analysts' price targets for Longboard Pharmaceuticals, Inc. (LBPH) points to a 208.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-03-02 23:12:01 - Seeking Alpha
Longboard Pharmaceuticals, Inc. (LBPH) Q4 2022 Results - Earnings Call Transcript
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH ) Q4 2022 Results Earnings Conference Call March 2, 2023 4:30 PM ET Company Participants Brandi Roberts - Executive Vice President and Chief Financial Officer Kevin Lind - President and Chief Executive Officer Randall Kaye - Executive Vice President and Chief Medical Officer Conference Call Participants Neena Bitritto-Garg - Citigroup Global Markets Josh Schimmer - Evercore ISI Charles Duncan - Cantor Fitzgerald & Co. Laura Chico - Wedbush Securities Yatin Suneja - Guggenheim Securities Patrick Trucchio - H.C. Wainwright & Co., LLC Operator Good day and thank you for standing by.
2023-02-23 16:31:00 - Business Wire
Longboard Pharmaceuticals to Report Full Year 2022 Financial Results and Key Corporate Initiatives on March 2, 2023
SAN DIEGO--(BUSINESS WIRE)---- $LBPH #Epilepsy--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release 2022 financial results and provide a corporate update on March 2, 2023. The Company will host a conference call at 4:30pm ET (1:30pm PT) on the same day.
2022-11-23 10:32:56 - Seeking Alpha
Longboard Pharmaceuticals: Arena Team's Next Act Is Flying Under The Radar
Shares have fallen by nearly 70% since IPO. Leadership including President & CEO hails from Arena Pharmaceuticals (bought out by Pfizer for $6.7B last year, which still owns 23% of Longboard).